Effect of CPAP on airway reactivity and airway inflammation in children with moderate-severe asthma

Respirology. 2019 Apr;24(4):338-344. doi: 10.1111/resp.13441. Epub 2018 Nov 16.

Abstract

Background and objective: Asthma is characterized by airway hyperreactivity and airway inflammation. We previously demonstrated that adults with mild well-controlled asthma exhibited a marked decrease in airway reactivity (PC20 increased >2-fold) after using nocturnal continuous positive airway pressure (CPAP) for 1 week. If CPAP produces a similar suppression of airway reactivity in children with moderate-severe asthma, who require chronic use of corticosteroids, then this non-pharmacological therapy might provide a beneficial alternative or supplemental therapy in these subjects.

Methods: Children aged 8-17 years with moderate-severe asthma were treated with 4 weeks of nocturnal CPAP (8-10 cm H2 O) or sham CPAP (<2 cm H2 O). Adherence was monitored with a modem installed in the equipment or by memory cards. Airway reactivity, assessed by methacholine bronchial challenge, was measured prior to and following treatment.

Results: The percentage of subjects adherent to treatment was similar in both groups (19/27 CPAP vs 19/28 sham, ~70%). There was a tendency for PC20 to increase with treatment in both groups (3.0-5.3 mg/mL CPAP vs 3.2 to 4.3 mg/mL sham, P = 0.083); however, the change did not differ significantly between groups (P = 0.569).

Conclusion: We found that the 4-week treatment with nocturnal CPAP did not produce a twofold suppression of airway reactivity in children with moderate-severe asthma.

Trial registration: ClinicalTrials.gov NCT02396849.

Keywords: bronchial challenge; chronic mechanical strain; induced sputum; lung function.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Asthma / physiopathology
  • Asthma / therapy*
  • Bronchial Provocation Tests
  • Bronchoconstrictor Agents
  • Child
  • Continuous Positive Airway Pressure*
  • Female
  • Forced Expiratory Volume
  • Humans
  • Inflammation / physiopathology
  • Inflammation / therapy
  • Male
  • Methacholine Chloride

Substances

  • Bronchoconstrictor Agents
  • Methacholine Chloride

Associated data

  • ClinicalTrials.gov/NCT02396849